Who are Nanocrystalline silver's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): B (Clorhexidine 2%), Irrigation with PVI, PerioChip ®, The Chlorhexidine gluconate 0.05%, Chlorhexidine oral care, Cetylpyridinium Chloride Buccal Tablets.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/nanocrystalline-silver.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Nanocrystalline silver — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nanocrystalline silver (Nanocrystalline silver) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimicrobial agent. Area: Infectious Disease / Wound Care.

marketed Antimicrobial agent Infectious Disease / Wound Care Small molecule Live · refreshed every 30 min

Target snapshot

Nanocrystalline silver (Nanocrystalline silver) — University of Sorocaba. Nanocrystalline silver exerts antimicrobial effects by releasing silver ions that disrupt bacterial cell membranes and inhibit microbial growth.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Nanocrystalline silver TARGET	Nanocrystalline silver	University of Sorocaba	marketed	Antimicrobial agent
B (Clorhexidine 2%)	B (Clorhexidine 2%)	Instituto de Investigacion Sanitaria La Fe	marketed	Antimicrobial agent / Antiseptic
Irrigation with PVI	Irrigation with PVI	The University of Texas Health Science Center, Houston	marketed	Antiseptic/Antimicrobial agent
PerioChip ®	PerioChip ®	Dexcel Pharma Technologies Ltd.	marketed	Local antimicrobial agent	Bacterial cell membranes (chlorhexidine non-specific antimicrobial)
The Chlorhexidine gluconate 0.05%	The Chlorhexidine gluconate 0.05%	HaEmek Medical Center, Israel	marketed	Antimicrobial agent / Antiseptic
Chlorhexidine oral care	Chlorhexidine oral care	University of Pavia	marketed	Antimicrobial agent / Antiseptic	Bacterial cell membrane and proteins
Cetylpyridinium Chloride Buccal Tablets	Cetylpyridinium Chloride Buccal Tablets	Peking University People's Hospital	marketed	Quaternary ammonium antimicrobial agent	Bacterial cell membrane

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimicrobial agent class)

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · 1 drug in this class
SIFI SpA · 1 drug in this class
Universidad Miguel Hernandez de Elche · 1 drug in this class
University of Sorocaba · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Nanocrystalline silver — Competitive Intelligence Brief. https://druglandscape.com/ci/nanocrystalline-silver. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing